

ASX RELEASE (1 JUNE 2020)

Tetra Health Acquisition Completed and Products Launching

Investment Highlights:

- Acquisition of Tetra Health, a leading clinic provider enabling access to medicinal cannabis for Australian patients, completed
- Tetra to enable access to THC Global's Canndeo products commencing with recently launched CBD medicines
- Tetra has a network of over 600 physicians, and database of over 10,000 prospective patients with over 1,000 currently prescribed medicinal cannabis
- Tetra offers a low cost option for patients looking to consider medicinal cannabis, with low cost consultations and referral options for their existing doctors
- Canndeo's recently launched full spectrum CBD medicine now available for prescription and supply within Tetra Health's prescriber and pharmacy network to increase affordability
- Tetra collects real world patient data of high value for future product registration

THC Global Group Limited (**THC Global** or the **Company**) (ASX:THC) is pleased to confirm that the acquisition of Tetra Health (**Tetra**) by the Company has now completed. Tetra is a leading Australian clinic network facilitating access to legal medicinal cannabis medicines for Australian patients. Tetra's network has over 600 referring physicians, 30 prescribing physicians, and a national network of dispensing pharmacies.

Tetra will make Canndeo's medicinal cannabis products available through its network, commencing with Canndeo's full spectrum CBD range and expanding to additional products as they are launched by Canndeo. Availability of Canndeo products continues alongside Tetra's continued supply of other brands of medicinal cannabis medicines.

Affordability and accessibility remain key barriers to patient uptake of medicinal cannabis within Australia. By combining quality with affordability with its Canndeo range of medicines, THC Global expects patient uptake to increase significantly. Further, with over 45% of Tetra's patients using a Cannabidiol (CBD) dominant medicine, THC Global's first full-spectrum CBD medicine launched last week, and the new CBD isolate medicine expected to launch in the coming weeks, are both expected to be highly attractive to Australian patients and prescribers.

In addition to facilitating the legal access to medicinal cannabis medicines for Australian patients, Tetra Health also collects highly sought after real world evidence through the patient onboarding and management process. The data will assist THC Global in making data driven product decisions, as well as actionable treatment insights to assist in clinical trials or observational study designs enhancing the safety and efficacy data on these medicines. THC Global anticipates this will further the Company's pursuit of product registration in Australia.

Tetra Health Chief Operating Officer, Diandra Phipps said: "We are delighted to introduce THC Global's wholly Australian sourced CBD medicine to our existing product range. In the last month, we've seen a 40% increase in new patients as we have temporarily reduced our treatment fees, reflecting the current economic conditions. With the further reduction in patient costs with THC Global's full spectrum CBD medicines launch, Tetra is expecting to deliver a significant increase in patient accessibility to medicinal cannabis medicines in Australia."

For further information, please contact:

Ken Charteris
Chief Executive Officer
e: ceo@thc.global

Sonny Didugu & Jarrod White
Joint Company Secretaries
e: corporate@thc.global
p: +61 2 8088 4760

The Capital Network
Julia Maguire
e: julia@thecapitalnetwork.com.au
p: + 61 2 8999 3699

ASX release authorised by THC Global's Management Committee – the Chairman, Deputy Chairman, and CEO.

THC Global Group Limited (ASX: THC) thc.global

THC Global is a diversified global cannabis company with primary operations in Australia and Canada. THC Global is the first ASX listed entity to fully own and operate end to end commercial medicinal cannabis production facilities under Australia's cannabis regulations. THC Global's Southport Facility is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world. THC Global also owns and operates Crystal Mountain, a fast growing hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sector in North America and Europe.

For prospective patients or healthcare professionals seeking more information on medicinal cannabis, please visit: canndeocare.com and tetrahealth.com.au.